Phenylthiocarbamoyl-serin | 94074-67-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Phenylthiocarbamoyl-serin
• 英文别名: 3-Hydroxy-2-(phenylcarbamothioylamino)propanoic acid
• CAS: 94074-67-6
• 化学式: C₁₀H₁₂N₂O₃S
• 分子量: 240.283
• InChiKey: QBPWFRZRKIZLGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Method and use of metabolites for the diagnosis of inflammatory brain injury in preterm born infants
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2492690A1

  公开（公告）日：2012-08-29

  The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.

  本发明涉及预测早产儿发生炎症相关脑损伤可能性的新型生物标记物，该标记物使用选自酰基肉毒蛋白、二酰基磷脂酰胆碱、酰基烷基磷脂酰胆碱、溶血磷脂酰胆碱和氨基酸组成的组中的多种内源性靶代谢物。
• METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS
  申请人：InfanDx AG

  公开号：EP2678690B1

  公开（公告）日：2018-01-24
• Method and Use of Metabolites for the Diagnosis of Inflammatory Brain Injury in Preterm Born Infants
  申请人：Keller Matthias

  公开号：US20140297195A1

  公开（公告）日：2014-10-02

  The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.
• [EN] METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS<br/>[FR] UTILISATION DE MÉTABOLITES POUR LE DIAGNOSTIC DE LÉSIONS CÉRÉBRALES INFLAMMATOIRES CHEZ LES NOUVEAU-NÉS PRÉMATURÉS ET PROCÉDÉ ASSOCIÉ
  申请人：BIOCRATES LIFE SCIENCES AG

  公开号：WO2012113834A1

  公开（公告）日：2012-08-30

  The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.